1154 related articles for article (PubMed ID: 12677170)
1. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
2. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.
Pappu AS; Illingworth DR
J Lab Clin Med; 1989 Nov; 114(5):554-62. PubMed ID: 2809398
[TBL] [Abstract][Full Text] [Related]
3. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
4. [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia].
Prat H; Román O; Pino E
Rev Med Chil; 1999 Mar; 127(3):286-94. PubMed ID: 10436712
[TBL] [Abstract][Full Text] [Related]
5. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
7. Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia.
Pappu AS; Illingworth DR; Bacon S
Metabolism; 1989 Jun; 38(6):542-9. PubMed ID: 2725293
[TBL] [Abstract][Full Text] [Related]
8. [HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
Geisel J; Oette K; Burrichter H
Fortschr Med; 1990 Feb; 108(4):71-2, 75-6. PubMed ID: 2312032
[TBL] [Abstract][Full Text] [Related]
9. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
[TBL] [Abstract][Full Text] [Related]
10. [Effects of simvastatin on atherogenic blood lipid pattern].
Alessandri C; Peverini F; Basili S; Barsi R; Paradiso M; Marotta P; Censi C; Cordova C; Balsano F
Recenti Prog Med; 1991 Apr; 82(4):225-9. PubMed ID: 1857842
[TBL] [Abstract][Full Text] [Related]
11. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
Saxenhofer H; Weidmann P
Ther Umsch; 1990 Jun; 47(6):509-13. PubMed ID: 2375007
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
Darioli R; Bovet P; Brunner HR; Bercher L
Schweiz Med Wochenschr; 1990 Jan; 120(4):85-91. PubMed ID: 2305221
[TBL] [Abstract][Full Text] [Related]
13. The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia.
Prihoda JS; Pappu AS; Smith FE; Illingworth DR
J Clin Endocrinol Metab; 1991 Mar; 72(3):567-74. PubMed ID: 1847705
[TBL] [Abstract][Full Text] [Related]
14. The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia.
Pappu AS; Illingworth DR
Atherosclerosis; 2002 Nov; 165(1):137-44. PubMed ID: 12208479
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease.
French JK; White HD; Greaves SC
N Z Med J; 1990 Feb; 103(883):41-3. PubMed ID: 2304688
[TBL] [Abstract][Full Text] [Related]
16. [Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin].
Brocard JJ; Keller U; Oberhänsli A; Riesen WF
Schweiz Med Wochenschr; 1991 Jun; 121(26):977-83. PubMed ID: 1862314
[TBL] [Abstract][Full Text] [Related]
17. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Branchi A; Rovellini A; Fiorenza AM; Sommariva D
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
[TBL] [Abstract][Full Text] [Related]
18. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up].
Wenke K; Thiery J; Meiser B; Arndtz N; Seidel D; Reichart B
Z Kardiol; 1995 Feb; 84(2):130-6. PubMed ID: 7717016
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.
Leclercq V; Harvengt C
Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):76-81. PubMed ID: 2921098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
